Reuters logo
BRIEF-Eiger Biopharmaceuticals appoints Lisa Porter to lead development of Exendin 9-39
April 18, 2017 / 12:13 PM / 5 months ago

BRIEF-Eiger Biopharmaceuticals appoints Lisa Porter to lead development of Exendin 9-39

April 18 (Reuters) - Eiger Biopharmaceuticals Inc

* Eiger Biopharmaceuticals Inc - appointment of Lisa Porter to lead development of Exendin 9-39 for treatment of post-bariatric hypoglycemia

* Eiger Biopharmaceuticals - evaluating new Exendin 9-39 liquid formulation in patients in ongoing mad study and also in a phase 1 PK study scheduled for Q2 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below